Juyar da tsufa: kimiyya
A cikin shekarun da suka gabata, masana kimiyya sun yi kokarin gano yadda za a iya rage yawan mutuwar mutane sakamakon cututtukan da suke haifarwa. Amma har yanzu ba a samu wani abu mai kyau ba.
Snuupo / Wikimedia Commons (CC BY-SA 4.0)
A cikin tarihin, mutane sun mutu suna kanana saboda cututtuka da raunuka da haihuwa. A yau, a cikin mafi yawan duniya, suna mutuwa da tsufa, kuma suna mutuwa daga jerin ƙananan cututtukan da suka fi tsanani: cututtukan zuciya, ciwon zuciya, kwayar cutar kansa, rashin hankali, cututtukan sukari da cututtukan huhu. Ga kõwace daga cikin waɗannan cututtuka akwai ƙwararrunsu, da kyautatawa da magunguna. Amma suna raba wani babban abin da ke haifar da haɗari, kuma ba shan sigari, abinci ko jinni ba ne. Wannan shi ne girma. Wani fanni na kimiyya mai bunkasa, wanda ake kira geroscience, yana tambayar wata tambaya mai sauƙi: a maimakon mu yi yaki da kowace cuta ta tsufa daban-daban, shin za mu iya rage yanayin tsufa da ke tafiyar da su duka? Wannan shafi na bayyana, kamar yadda ya dace da gaskiya da kuma yadda za mu iya, abin da wannan bincike ya nuna, abin da bai nuna ba, da kuma abin da zai iya nufin ga dukkanmu.
Me ya sa tsufa ita ce tushen mafi yawan cututtukan da ke ci gaba
Ka duba kusan kowace cuta mai tsanani ta hanyar shekaru kuma irin wannan siffar zata bayyana: ba ta da yawa a cikin matasa, sa’an nan kuma tana karuwa da sauri tare da kowane ƙarni. A cikin Amurka a 2025, kusan kashi 0.5 na manya masu shekaru 18 zuwa 44 sun kasance an gano su da cutar zuciyar coronary; tsakanin mutane masu shekaru 75 da suka wuce shi ne kashi 19%. Duk wani ciwon daji: kashi 2 bisa dari a kan kashi 33. Artritis: kashi 6 bisa dari a kan kashi 53 cikin dari (NCHS, NHIS 2025). Ana samun karin kamuwa da ciwon daji daga kimanin 236 ga 100,000 mutum a shekara a shekarun 40 zuwa 44 zuwa kimanin 2,400 a 80 zuwa 84 (NCI SEER). Shirin mutane da ke rayuwa da cututtukan zuciya ya ninka kusan sau biyu a kowace shekara biyar zuwa shida bayan 65, yana kaiwa kusan daya cikin uku a shekaru 90 da suka wuce (Manly et al., 2022).
A cikin bayanan Amurka a sama, cututtukan zuciya na coronary suna da yawa fiye da sau 38 a kan 75 da kuma sama da 18 zuwa 44. Wannan shi ne dalilin da ya sa wata ƙungiya ta manyan masu bincike suka bayyana tsufa a matsayin “mafi girman abin da ke haifar da haɗari ga mafi yawan cututtukan da ba a warkewa” kuma sun yi shawara cewa magance tsufa na kansa zai iya jinkirta yawa daga cikinsu (Kennedy et al., 2014). Wannan shi ne gidanka na tattalin ilmi. Kuma akwai wata azãba mai tsanani. Maganin wata cuta ta tsufa yana kara rayuwar mutum kadan, saboda sauran su na jiran magani: mutane da aka ceto daga ciwon zuciya suna fuskantar cutar kansa, ko kuma rashin hankali ko kuma rauni a shekaru kaɗan masu zuwa. Kuma idan ka dakata wa tsufa, to, zã ka mayar da su gabã ɗaya a lokaci guda.
Masu kimiyya sun yi kokarin sanya darajar wannan. Wani bincike na 2013 a Amurka ya gano cewa dakatarwar da ta yi tsawo a cikin tsufa za ta ƙara kusan shekaru 2.2 na fatan rayuwa, mafi yawansu masu lafiya, suna da darajar kusan $ 7.1 trillion a cikin shekaru 50 (Goldman et al., 2013). Wani bincike na 2021 ya kiyasta cewa rage girman gaske don ƙara shekara daya na fatan rayuwa zai zama da daraja $38 trillion to the US, and ten years $367 trillion (Scott, Ellison da Sinclair, 2021). Waɗannan su ne nau’ikan da aka gina a kan zarge-zarge, amma suna nuna dalilin da ya sa gwamnatocin da masu zuba jari suke ba da hankali.
Abin da yake faruwa a gaskiya: alamomin tsufa
Tsanani bai zama hanya guda ba, amma da yawa, suna faruwa tare kuma suna ciyarwa da jũna. A shekarar 2013 wata ƙungiya mai jagorancin Carlos López-Otín ta haɗa su cikin alamomin da ke nuna tsufa tara, kuma a shekarar 2023 ta fadada jerin zuwa goma sha biyu (López-Otín et al., 2013; López-Otín et al., 2023). A cikin magana bayyananna.
- Genomic instability: damage to DNA builds up faster than it is repaired.
- Telomere attrition: the protective caps on the ends of chromosomes wear down.
- Epigenetic alterations: the chemical marks that switch genes on and off drift out of their youthful pattern.
- Loss of proteostasis: proteins fold wrongly and clump together.
- Macroautophagy mara aiki: tsarin sake amfani da kwayoyin halitta ya yi sauri.
- Deregulated nutrient sensing: growth signals such as mTOR and insulin stay switched on when repair would be better.
- Mitochondrial dysfunction: cell’s power stations make less energy and more harmful by-products.
- Cellular senescence: damaged cells stop dividing but refuse to die, and release inflammation signals.
- Stem cell exhaustion: the reserves that repair tissues run down.
- Saƙonnin da aka canza tsakanin ƙwayoyin halitta: alamun tsakanin ƙwayoyin halitta da organs sun ɓace.
- Chronic inflammation: wani ƙaramin, ciwon ciki mai tsanani, wanda a wasu lokuta ake kira “inflammageing”.
- Dysbiosis: the balance of microbes in the gut shifts.
Duk wani tsari a kan wannan shafi yana da nufin daya ko fiye daga cikin waɗannan alamomin. Kuma lalle ne, haƙĩƙa, Allah Ya saukar da wani littafi mai tsarki ga mutãne waɗanda suke sani. Lalle ne, Allah Mai hikima ne, Mai jin ƙai. Wannan gwajin na karshe shi ne inda fatan yake fitowa daga, saboda ga wasu daga cikin waɗannan hanyoyi, masu bincike sun riga sun yi shi a cikin dabbobi.
Shin, mun tabbata? A kan wani ma’auni na shaidar
Kalmar “anti-aging” tana rufe duk wani abu daga halaye da aka tabbatar a cikin miliyoyin mutane zuwa ra’ayoyi da aka gwada a cikin binciken kifi guda. Don a kiyaye su daban, kowace hanya a wannan shafi tana da ɗaya daga cikin matakai huɗu:
- An tabbatar da shi a cikin mutãne: bincike mai girma na mutum da kuma gwaje-gwajen da aka yi a kan randomized sun nuna cututtuka da mutuwa kaɗan.
- Promising human trials: randomised trials in people show real effects, but not yet on ageing itself.
- Strong in animals: repeated, robust results in animals; human evidence small, mixed or just starting.
- Early ko speculative: mai rauni, da aka yi musu tambayar ko shaidar karatu guda ɗaya, ko kuma gwaje-gwajen mutum har yanzu ba tare da amfanin bayyananne ba.
To be clear: nothing on this page has yet been shown to slow or reverse human ageing as a whole. No drug, supplement or gene therapy is approved to treat ageing anywhere in the world. To, don me ma’abũta ilmi suke yin farin ciki? Saboda shekaru ashirin da suka gabata ba a san wani wanda zai iya fadada rayuwar dabba mai kwakwalwa ta dabi’a da magani ba, kuma yanzu wasu magunguna na yin hakan, a cikin gwaje-gwajen da aka yi la’akari da su a cikin masana’antu daban-daban; saboda za a iya sanya kwayoyin halittar da ke da shekaru suyi aiki kamar waɗanda suke da shekaru kaɗan a cikin kwanon rufi kuma, a cikin wasu ƙwayoyin, a cikin dabbobi masu rai; kuma saboda gwaje-gwajen farko na mutum da aka tsara don nazarin kimiyyar tsufa, fiye da cutar daya, suna gudana a halin yanzu. Hanyar daga kifi zuwa ga mutum mai tsawo ce, kuma mãsu yawa daga hanyoyi mãsu alkawari sun kãsa a kanta. Kuma shiriya bayyananne ce.
Nutrient sensing: mTOR and rapamycin
Evidence grade: promising human trials
Mene ne shi. Duk wani kwayoyin halitta yana da bukatar ya yanke shawarar ko zai girma ko kuma zai gyara kansa. Wani kwayoyin halitta mai suna mTOR (wanda ake kira da ra’ayin mechanistic na rapamycin) yana yin wannan kiran: lokacin da abinci da alamun girma sun yi yawa, mTOR ya ce “ya girma”; Idan sun yi yawa, sai ya koma baya kuma kwayar ta canza zuwa kulawa, ciki har da sake amfani da sassan da suka lalace ta hanyar autophagy. A cikin rayuwarsu ta girma, mTOR na da niyyar zama a kan shiri fiye da yadda yake da kyau ga mu. Kuma lalle ne, haƙĩƙa, Allah Ya saukar da wani littafi mai tsarki ga ManzanninSa, kuma ya sanya su mãsu bãyar da lãbãri.
Rapamycin shi ne magani wanda ke hana mTOR. An gano shi a cikin wani misalin ƙasa daga Rapa Nui (Easter Island), wanda ya ba da sunansa, inda aka yi shi ta hanyar kwayoyin cuta, Streptomyces hygroscopicus (Vézina, Kudelski da Sehgal, 1975). A cikin maganin da aka yi amfani da shi na shekaru da dama don hana jikin mutum ya ki karbar wasu organs.

Kuma a cikin dabbõbi. A cikin 2009, cibiyar binciken gwajin da aka yi a Amurka ta National Institute on Aging’s Interventions Testing Program, wadda ke gwada sinadarai a cikin kifi masu bambanta da juna a cikin labaran biyu na labaran likitanci a lokaci guda, ta bayyana cewa rapamycin ya tsawaita rayuwar har ma lokacin da aka ba shi a farkon rana 600, ƙarshe a cikin rayuwar kifi. Daga wannan shekarun, tattalin rayuwar ya karu da kashi 28 cikin dari a maza da kashi 38 cikin dari a mata (Harrison et al., 2009). A cikin wani magani mai girma da aka fara a cikin shekarun tsakiyar, adadin rayuwar ya karu da kashi 23 cikin dari a cikin maza da kashi 26 cikin dari a cikin mata (Miller et al., 2014). Rapamycin shi ne maganin da ya fi dacewa a yi amfani da shi wajen rage yawan mutuwar dabbobi, kuma yana daya daga cikin magunguna masu tsawo a duniya.
A cikin mutãne. Wani dalili na mutum ne kaɗan amma gaskiya. A cikin wani bincike na randomized a cikin masu zaman kansu, makonni shida na everolimus, wani ma’aikacin da ke kusa da rapamycin, ya inganta amsawa ga allurar rigakafin kwalara ta kusan kashi 20 (Mannick et al., 2014), kuma wani binciken da ya biyo baya na wani haɗin gwiwar da ke da alaƙa ya rage kamuwa da cuta a cikin shekara mai zuwa (Mannick et al., 2018). Amma wani bincike mai girma na matakin 3 na maganin da ya dace, a cikin mutane sama da 1,000 masu shekaru, bai sami raguwar cututtukan huhu ba (Mannick et al., 2021). A cikin binciken PEARL, an baiwa masu lafiya maganin rapamycin na mako-mako mai ƙarancin kashi a kowace mako na 48 makonni. Ba ta canza ma’auninta na farko, visceral fat, kuma sakamako masu illa sun yi kama da placebo; wasu matakai na biyu, kamar yadda lean muscle a cikin mata akan mafi girman dosi, ya inganta (Moel et al., 2025). A 2024 nazarin 19 bincike ya gano babu wani mummunan al’amari a cikin mutane masu lafiya, amma fiye da cututtuka da mafi girman jini a cikin mutane waɗanda suka riga sun kasance da cutar da ke da alaƙa da shekaru ([Lee, Kuerec da Maier, 2024](https://doi.org/10.1016/S2666-7568(23) 00258-1)).
Risks. A transplant shirye-shirye, rapamycin ya hana tsarin rigakafi da kuma ɗaukar gargaɗi game da cututtuka masu tsanani da wasu kwayoyin cuta. Kuma, a cikinsa akwai wani abu mai kyau da kuma wani abin baƙin ciki.Label). A cikin kifi, amfani mai tsawo yana haifar da juriya ga insulinu (Lamming et al., 2012). Masu bincike suna gwada allurai masu ƙaranci da na lokaci-lokaci, da kuma maganin rigakafi wanda ke hana ɓangaren mTOR kawai wanda ya danganta da tsawon rai.
Senolytics: tsaftace “zombies” cells
Evidence grade: strong in animals
Mene ne shi. Idan wata kwayar halitta ta yi rauni mai tsanani, za ta iya shiga cikin wani hali da ake kira sansenescence: tana daina rabawa, wanda ke kareta daga ciwon daji, amma ba ta mutu ba. Sanin halittu suna ƙãrãwa da tsufa. Worse, they release a cocktail of inflammatory signals, the senescence-associated secretory phenotype (SASP), that harms the healthy cells around them (Coppé et al., 2008). Senolytics sune magunguna da aka tsara don kashe ƙwayoyin cuta na senescent ta hanyar zaɓa.

Kuma a cikin dabbõbi. A shekarar 2011, masu bincike sun yi injiniyanci kan kifi don a iya cire kwayoyin halittarsu masu tsufa idan aka bukace su. Clearing them delayed age-related damage in fat, muscle and the eye (Baker et al., 2011). A cikin kifi na yau da kullum, cire waɗannan ƙwayoyin daga tsakiyar shekaru ya rage tsawon rayuwarsu ta kashi 24 zuwa 27 (Baker et al., 2016). An samu farkon hadin maganin senolytic, dasatinib da quercetin, a cikin 2015 (Zhu et al., 2015). An ba da shi ga kwayoyin ƙwayoyi masu tsawo, ya inganta aikin jiki kuma ya ƙara tsawon rayuwar da ke rage da kashi 36 (Xu et al., 2018). Fisetin, wani sinadari na halitta wanda aka samu a cikin strawberries, ya faɗaɗa rayuwar lokacin da aka ba wa kwayoyin ƙwayoyi masu tsawo (Yousefzadeh et al., 2018).
A cikin mutane. Na farko sakamakon mutum ne mai ƙaranci da haɗe-haɗe. A cikin mutane 14 da ke da cutar huhu, fibrosis na huhun idiopathic, makonni uku na dasatinib tare da quercetin sun inganta tafiyar da gudu da sauri, kodayake ba aikin huhu ba, a cikin wani bincike ba tare da rukunin placebo ba (Justice et al., 2019). A cikin mutane tara da ke fama da ciwon sukari na kifi, magunguna sun rage ƙwayoyin cuta a cikin fat da fata kuma sun rage alamun inflammation a cikin jini (Hickson et al., 2019). Amma a cikin wani bincike na kwarara a kan mata masu shekaru 60, magunguna ba su inganta ƙashi ba; kawai matan da suke da mafi yawan ƙwayoyin cuta sun yi kama da amfani (Farr et al., 2024). A cikin wani bincike na yiwuwar a cikin mutane biyar da ke da cutar Alzheimer, dasatinib ya isa ruwa a kusa da kwakwalwa amma quercetin bai yi ba (Gonzales et al., 2023). Mafi girma fisetin gwaje-gwajen a kan Mayo Clinic suna ci gaba da aiki (NCT03675724).
Kamfanin farko da aka gina a kusa da senolytics, Unity Biotechnology, ya gwada allurar ido, UBX1325 (foselutoclax), don cutar ido ta diabetik. Bayan wani bincike na farko mai ban sha’awa, wani bincike na matsakaicin 2 wanda ya kwatanta shi da maganin standard ya rasa manufarsa ta farko (Unity Biotechnology, 2025), kuma kamfanin ya lalace a ƙarshen wannan shekara (SEC filing, 2025).
Risks. Dasatinib shi ne maganin cutar kansa da ke da illa mai tsanani, ciki har da illa ga adadin jini. Sanin sel suna da ayyukan amfani, misali a cikin warkar da rauni, don haka tsaftace su ba tare da haɗari ba ne.
NAD+, NMN and NR
Evidence grade: early or speculative
Mẽne ne ita? NAD+ wani molekiul mai ƙarancin girma ne wanda kowace kwayar halitta ke buƙata don canza abinci zuwa makamashi da kuma gyaran DNA. Yana da matsakaicin zafi, kuma yana da ƙarancin sanyi. An sayar da wasu abubuwa biyu da jikin mutum zai iya juya su zuwa NAD+, nicotinamide mononucleotide (NMN) da nicotinamide riboside (NR), a matsayin kayan haɗin.
In animals. In mice, a year of NMN in drinking water eased several age-related changes, including weight gain and declining energy use (Mills et al., 2016), and NR improved mitochondrial and stem cell function and modestly lengthened life in old mice (Zhang et al., 2016). Amma lokacin da shirin gwajin Interventions ya gwada NR tare da zane mai tsanani, bai fadada rayuwarsa ba a cikin kowane jinsi (Harrison et al., 2021).
A cikin mutane. NR da NMN suna kara NAD+ a cikin jini (Martens et al., 2018). Mafi kyawun binciken da aka sani ya ba NMN ga mata 25 tare da prediabetes na makonni goma: jinkirin insulinin ƙwayar cuta ya inganta da kashi 25 cikin ɗari, yayin da ƙarfin jini, fatar jini da ƙirar jiki ba su canja ba (Yoshino et al., 2021). A cikin wani bincike mai ƙarancin gaske a kan cutar Parkinson, NR ya kara NAD a cikin kwakwalwa tare da ingantacciyar ci gaba ta likita (Brakedal et al., 2022); wani bincike mai girma ya ƙare kuma sakamakonsa ana jiran sa. Reviews that pool the trials so far find the supplements safe in the short term but with mostly no clear benefit for blood sugar, blood fats or muscle (Zhang et al., 2025; Prokopidis et al., 2025). Abin da ba a nuna: cewa haɓaka NAD + yana rage tsufa ko hana kowane cuta a cikin mutane.
Regulation. A cikin 2022, Hukumar Kula da Abinci da Magunguna ta Amurka ta ce NMN ba za a iya sayar da shi ba kamar yadda ake karatun magani; a watan Satumba na 2025 ya juya wannan ra’ayi (FDA, 2025). A kan sayarwa ba ya faɗar komai game da ko wani abu yana aiki.
Sirtuins da resveratrol labarin
Evidence grade: early or speculative
Mẽne ne ita? Sirtuins wani dangin enzymes ne, bakwai a cikin dabbobin jin dadin ci, waɗanda ke amfani da NAD+ don kula da gyara DNA, metabolism da kuma aikin gene. A cikin 2003 wata bincike ya bayyana cewa Name=KDevAdaProject, wani sinadari da aka samu a cikin red zaƙi, activated a sirtuin kuma ya tsawaita rayuwar na ƙwai (Howitz da sauran su, 2003). A cikin 2006 resveratrol ya inganta lafiya da rayuwa na kifi a kan abinci mai yawan calorie (Baur et al., 2006). A shekarar 2008, kamfanin magunguna na GSK ya saya Sirtris, wata kamfani mai haɓaka masu kunna sirtuin, da dala miliyan 720 (GSK da Sirtris, 2008).
Me yasa ya fadi. Labarin bai tsaya da kyau ba. Resveratrol bai kara tsawon rayuwar kifi na yau da kullum ba a kan abinci mai kyau (Pearson et al., 2008), ciki har da shirin gwajin gwaji (Miller et al., 2011). Biochemists sun gano cewa aikace-aikacen bayyananne na sirtuin SIRT1 ya dogara ne akan wata alama ta halitta mai haske da aka yi amfani da ita a cikin gwajin (Kaeberlein et al., 2005; Pacholec et al., 2010). Kuma tasirin rayuwar asali na sirtuin na musamman a cikin ƙwayoyi da kwari ya ɓace sosai lokacin da aka kula da yanayin ilimin halitta (Burnett et al., 2011).
What remains credible. Sirtuins still matter. Kwayoyin da aka tsara don yin fiye da sirtuin guda, SIRT6, sun rãyu tsawon lokaci: maza kawai a cikin binciken farko (Kanfi et al., 2012), kuma a wani bincike na ƙarshe kashi 27 cikin dari mafi tsawo a cikin maza da kashi 15 cikin dari a cikin mata, tare da ƙarancin rauni (Roichman et al., 2021). Wannan ita ce ilimin halitta, ba magani ba ne. Ba a nuna wani ƙari na sirtuin-activating don rage tsufa a cikin mutane ba.
Telomeres and telomerase
Evidence grade: early or speculative
Mẽne ne ita? Telomere su ne sassa masu maimaituwa na DNA da ke rufe ƙarshen kromosomanmu, kamar yadda aka yi da maɓallan plastik a kan ƙafafun takalma. Sunã ragewa da ɗanɗano a kõwane lõkacin da mafi yawan ƙwayoyin ke yin raba; idan sun yi yawa, sai ƙwayar ta hanu daga yin raba ko kuma ta mutu. An yi amfani da telomerase don yin wannan. Elizabeth Blackburn, Carol Greider da Jack Szostak sun raba kyautar Nobel ta 2009 a fannin kimiyya ko likitanci don gano yadda wannan yake aiki (Nobel Prize, 2009).

Kuma a cikin dabbõbi. A shekarar 2012, wata tawaga daga Cibiyar Binciken Kanjamau ta Kasa ta Spain ta ba da maganin halittar kwayoyin halitta ga kifi mai girma wanda ya sake kunna telomerase. Median rayuwa ya karu da kashi 24 cikin dari a cikin kifi da aka yi magani a shekara daya da kuma kashi 13 cikin dari a cikin kifi da aka yi magani a shekaru biyu, ba tare da wani karin a kanjamau (Bernardes de Jesus et al., 2012). Wannan ya ci gaba da zama wani abu mai muhimmanci amma ba a sake yin irinsa ba.
Matsalolin Kansa. Kwayoyin cuta na bukatar su raba kansu ba tare da iyaka ba, kuma mafi yawansu suna yin hakan ne ta hanyar kunna telomerase: a cikin wata bincike mai ban sha’awa, 90 daga cikin 101 na kwayoyin cuta sun kasance masu aiki da telomerase, kuma babu ɗaya daga cikin 50 na ƙwayoyin halitta na yau da kullum (Kim et al., 1994). Mutanen da ke dauke da kwayoyin halittar da suke ba su telomeres masu tsawo suna da haɗarin kamuwa da cututtukan zuciya na coronary amma suna da haɗarin kamuwa da cututtukan kansa da yawa, ciki har da glioma, adenocarcinoma na huhu da melanoma (Haycock et al., 2017). Telomere mai gajeren lokaci ba kawai “masu kyau” ba ne kuma masu tsawo “ma’ana”.
A cikin mutãne. Kuma waɗanda suka yi ĩmãni, su aikata ayyukan ƙwarai, kuma su tsare abin da Allah Ya haramta.Armanios da Blackburn, 2012). A cikin wani bincike a kan waɗannan marasa lafiya, danazolol na hormone ya faɗaɗa telomeres a cikin 11 daga cikin mutane 12 waɗanda za a iya tantance su (Townsley et al., 2016). Wannan shi ne magani ga wata cuta da ba ta da yawa, ba don tsufa ba. Ka yi shakka kan duk wani zargin cewa wani abu ko asibiti “ya fadada telomeres ka” don ya sa ka zama dan karami: a cikin 2015 shugaban wata kamfani ya ce ta samu maganin jinya na telomerase wanda ba a tabbatar da shi ba a waje, amma duk da haka, ba a taba tabbatar da wannan zargi ba a cikin bincike mai nazari (MIT Technology Review, 2015).
Reprograming na ɓangare da ma’aurata Yamanaka
Evidence grade: strong in animals, first human trial under way
Mene ne shi. A shekarar 2006 Shinya Yamanaka ta nuna cewa, sauyawa akan jikoki hudu kawai, yanzu ana kiran su da Yamanaka factors (OCT4, SOX2, KLF4 da c-MYC, ko OSKM), yana mayar da wata ƙwayar fata mai girma zuwa ƙwayar halitta mai kama da kwayar halitta wadda za ta iya zama kowane nau’in ƙwayar halitta (Takahashi da Yamanaka, 2006). Ya raba kyautar Nobel ta 2012 don shi (Nobel Prize, 2012). A kan hanyar, shekarun kwayoyin halitta ana cire su: alamun sinadarai a kan DNA na dawo da wani tsari mai danko. Aikin da ake yi na sake tsarawa ta ɓangare shi ne a kunna ma’aunin kawai cikin ɗan lokaci, mai tsawo da zai iya sake saita alamun shekaru amma ba mai tsawo da zai iya hana sel ya manta da abin da yake.

Kuma a cikin dabbõbi. A cikin 2016, kifi da ya girma a baya an ba shi OSKM a cikin sifofi, kwanaki biyu da kuma kwanaki biyar. Their organs showed fewer signs of ageing and they lived longer (Ocampo et al., 2016). A cikin 2020, uku daga cikin abubuwan da suka shafi (OSK, barin c-MYC mai alaƙa da kwayar cuta) an aika su zuwa ga idanun kifi tare da rauni mai kama da glaucoma da na kifi masu shekaru, kuma an dawo da ganinsu ta hanyar sake kunna alamun a kan DNA na ƙwayoyin jijiyoyinsu (Lu et al., 2020). Longer-term partial reprogramming in normal ageing mice shifted many molecular markers towards a younger state (Browder et al., 2022), and in one small study, an OSK gene therapy given to very old male mice doubled their remaining median lifespan (Macip et al., 2024).

Risks. Going too far is dangerous. A lokacin da aka kunna abubuwan a hankali a cikin kifi mai rai, kwayoyin sun rasa alamunsu kuma suka samar da kwayoyin cuta masu suna teratomas (Abad et al., 2013); a wata bincike ta daban, OSKM na ci gaba ya haifar da rashin lafiyar jijiya da ƙwayar ciki da mutuwar cikin mako guda (Parras et al., 2023). Kula da adadin, lokacin da kuma waɗanne ƙwayoyin halitta ke karɓar waɗannan jinni shine babban kalubale.
Dakunan gwaje-gwajen da farko. Sashe na sake tsarawa ya jawo wasu daga cikin manyan saka hannun jari a cikin fasahar halittu. Altos Labs an fara shi a watan Janairu 2022 da $3 billion (Altos Labs, 2022). Retro Biosciences, backed with $miliyoyin 180 ta Sam Altman (MIT Technology Review, 2023), yana aiki kan sake tsarawa kuma ya ce maganinsa na farko, wani magani wanda ke nufin sake amfani da ƙwayoyin cuta, ya shiga wani matakin 1 na binciken a shekarar 2025 (Retro Biosciences, 2026). NewLimit ya tara dala miliyan 435 a shekarar 2026 kuma ya ce yana shirin yin nazarin farko na mutum na maganin ciwon daji (NewLimit, 2026). Maganin farko na sake tsarawa don isa ga mutane shine ER-100 daga Life Biosciences, wata maganin OSK gene da aka zuba a cikin ido don cututtukan biyu na nerve optic, glaucoma da non-arteritic anterior ischaemic optic neuropathy (NAION). Hukumar Kula da Abinci da Magunguna ta Amurka ta tabbatar da bincike a watan Janairu 2026 (Life Biosciences, 2026), kuma mai cutar farko an yi masa magani a watan Yunin 2026 a cikin binciken tsaro na matakin 1 na mutane 18 (ClinicalTrials.gov NCT07290244; Life Biosciences, 2026). Zai dauki shekaru.
Sauran manyan hanyoyi
Name=Dabarun da ke faɗaɗa rayuwar kifin
Evidence grade: strong in animals
Tun daga 2004, shirin gwajin Interventions ya gwada sinadarai 54 a cikin kifi fiye da 30,000 (Jiang et al., 2025). Tsarinsa mai tsauri ne: irin wannan gwajin yana gudana a cikin labaratoci uku, tare da kifi masu bambanta ta halitta, don haka sakamakon ya kamata ya tsaya a cikinsu duka. A gefen rapamycin, wasu sinadarai sun wuce: maganin ciwon sukari acarbose ya kara kashi 22 cikin dari ga tsawon rayuwar namiji amma kashi 5 cikin dari kawai a cikin mata (Harrison et al., 2014); 17-alpha-estradiol, wani nau’in estrogen mai rauni, ya ƙara kashi 19 cikin dari a cikin maza kuma babu komai a cikin mata (Strong et al., 2016); da maganin ciwon sukari canagliflozin ya ƙara kashi 14 cikin dari a cikin maza kawai (Miller et al., 2020). Rapamycin tare da acarbose ya ba da mafi girman riba har yanzu: kashi 34 cikin dari a cikin maza da kashi 28 cikin dari a cikin mata (Strong et al., 2022). Me ya sa maza ke amfana da wannan a mafi yawan lokuta shi ne wata tambaya mai muhimmanci. Ba a yi gwajin kowace daga cikin wadannan magunguna ba ga masu tsufa a cikin mutane.

Metformin and the TAME trial
Evidence grade: early or speculative
Metformin shi ne maganin cutar sukari mai arha da aka yi amfani da shi na fiye da shekaru sittin. A 2014 bincike na UK records lafiya gano cewa mutane da suka yi fama da ciwon sukari rike metformin rayuwa kaɗan fiye da daidaita mutane ba ciwon sukari (Bannister et al., 2014), wanda ya sa shi wani shugaban takarar ga anti-aging magani. An tsara binciken TAME (Targeting Aging with Metformin) don gwada ko yana jinkirta cututtukan zuciya, kwayar cutar, rashin hankali da mutuwar tare a cikin masu shekaru, kuma don yaudarar masu kula da su yi la’akari da tsufa kamar wani abu ne da magani zai iya shafar (Barzilai et al., 2016). A watan Satumba na 2026 ba mu iya samun sakamakon da aka wallafa ba. A cikin wannan lokacin, lamarin ya yi rauni: wani bincike na Denmark wanda ya haɗa da ‘ya’yan biyu bai gano wata dama ba ta rayuwa ga masu amfani da metformin (Keys et al., 2022); metformin kadai bai fadada rayuwar kifi ba a cikin shirin gwajin Interventions (Strong et al., 2016); kuma a cikin gwaje-gwajen biyu a cikin manya masu shekaru ya rushe amfanin horar da motsa jiki (Konopka et al., 2019; Walton et al., 2019).
GLP-1 medicines
Evidence grade: promising human trials
Waɗannan ƙwayoyin cuta suna dauke da wani sinadari mai suna GLP-1, wanda ke hana ciwon sukari da kuma nauyi. A cikin binciken SELECT na mutane 17,604 da ke fama da ciwon ciki da cutar zuciya, semaglutide ya rage kamuwa da cututtukan zuciya, raunuka da mutuwar jijiyoyin jini da kashi 20 (Lincoff et al., 2023). Wani bincike na Amurkawa masu fama da ciwon sukari ya danganta GLP-1 magani ga rage haɗarin halaye da yawa, ciki har da rashin hankali, sha’awa da cututtuka, da kuma ƙarancin haɗarin wasu, kamar matsalolin ciwo da ciwon pancreas (Xie, Choi da Al-Aly, 2025), amma irin waɗannan nazarin binciken ba za su iya tabbatar da dalili ba. Kuma a cikin gwaje-gwajen biyu masu girma a farkon cutar Alzheimer, Semaglutide na magana bai rage asarar ba (Cummings et al., 2026). Waɗannan ne magunguna mãsu ƙarfi ga cututtuka na musamman; ko kuwa su kange tsũfawa kansu ba a sani ba.
Calorie restriction
Evidence grade: promising human trials
Abincin kaɗan ba tare da rashin abinci ba yana faɗaɗa rayuwar nau’ikan halittu da yawa, kuma shi ne farkon “haɗin gwiwar anti-aging” da aka taɓa samu. A cikin tsuntsaye, manyan bincike biyu masu tsawon lokaci a farkon sun yi kama da rashin yarda, amma wani nazari mai haɗin gwiwa ya yanke shawarar cewa hana calorie yana inganta lafiya da rãyuwa idan an ɗauki bayanin abinci da shekaru (Mattison et al., 2017). A cikin CALERIE 2 bincike, 218 lafiya, non-obesitas mutane aka tambaye su su ci 25 bisa dari kaɗan ga shekaru biyu da kuma gudanar da kusan 12 bisa dari. Yawan jininsu, cholesterol da kuma jin dadin insulin sun inganta (Kraus et al., 2019), kuma wani ma’aunin gudun tsufa na halitta, DunedinPACE, ya raguwa da kashi 2 zuwa 3 cikin dari, kodayake wasu biyu ba su canja ba (Waziry et al., 2023). Rashin cin abinci mai gina jiki na iya haifar da rashin lafiyar jijiyoyi da ƙashi, kuma ba shi da aminci ga mutane masu cutarwa ko wadanda ke cikin hadarin kamuwa da cututtukan ciwon ciki, ko kuma ga matasa marasa lafiya.
Dabaru na musayar jini da plasma
Evidence grade: early or speculative
Idan an haɗa jijiyoyin kifi mai tsufa da kuma kifi mai ƙarancin shekaru, wasu daga cikin ƙwayoyin kifin da suka tsufa, kamar su ƙwayar jiki da kuma ciwon zuciya, suna gyara kansu mafi kyau (Conboy et al., 2005). An yi kira ga wani protin jini, GDF11, a matsayin abin da ke rage shekarun, amma aikin da ya biyo baya bai iya samar da sakamakon ba (Egerman et al., 2015). Wasu masu bincike yanzu suna tunanin cewa rage abubuwan da ke haifar da illa a cikin jinin da ya wuce shekarunsa yana da muhimmanci fiye da ƙarawa da waɗanda suke da shekaru: a cikin kifi masu shekaru, kawai sake maye gurbin rabin plasma tare da madara da magungunan albumin sun inganta ƙwayoyin jiki, ƙwayar zuciya da kuma kwakwalwa (Mehdipour et al., 2020). A cikin wani bincike mai ƙarancin placebo-controlled, sake maimaita therapy plasma exchange (sauya plasma da magungunan albumin) ya canja wasu wayoyin epigenetic zuwa ga wata shekara mai ƙaranci (Fuentealba et al., 2025), kuma a cikin wani binciken cutar Alzheimer’s ya rage raguwa a cikin ayyukan yau da kullun a cikin mutane masu cutar ta tsanani (Boada et al., 2020). A cikin 2019, Hukumar Kula da Abinci da Magunguna ta Amurka ta gargadi jama’a cewa infusions na plasma daga masu bada gudummawa matasa ba su da “farashin likitan da aka tabbatar” kuma suna ɗaukar haɗarin gaskiya (FDA, 2019).
Epigenetic clocks: measuring biological age
A kayan aiki na auna, ba wani magani
Don gwada ko wani abu na daure tsufa, masu bincike suna buƙatar hanyar auna shi ba tare da jira shekaru goma ba. Epigenetic clocks karanta alamun sinadarai (methylation) a ɗaruruwan wurare akan DNA kuma su kiyasta shekaru daga siffar. Na farko, daga Steve Horvath, ya yi aiki a kan dubban kwayoyin halitta (Horvath, 2013; Hannum et al., 2013). Bayan haka aka horar da wayoyin salula don yin hasashen lafiya fiye da shekarun kalanda: PhenoAge (Levine et al., 2018), GrimAge, wanda ke nuna lokacin mutuwar (Lu et al., 2019), da DunedinPACE, wanda ke kiyasta yadda sauri mutum yake tsufa yanzu, kamar mai sarrafa gudu (Belsky et al., 2022). Waɗanda suke da agogo suna tafiya a gaban shekarunsu suna mutuwa cikin sauri (Chen et al., 2016).
Abin da ba za su iya gaya mana ba: ko juyawa agogo baya zai sa mutum ya fi lafiya. Magani zai iya canja alamomin ba tare da canja halittar dake karkashinsu ba. Agogo na iya zama mai zafi: irin wannan misalin jini wanda aka auna sau biyu ya ba da karatu har zuwa shekaru tara, kodayake siffofin ingantattu sun rage wannan (Higgins-Chen et al., 2022). “Yara na halitta” gwaje-gwajen masu amfani suna da bambanci sosai kuma ba za su iya shirya shawarwari na likita ba.
Abin da aka tabbatar a yau a cikin mutane
Evidence grade: proven in people
A yayin da kimiyya ke ci gaba, mafi ƙarfin shaidar shekaru masu lafiya suna zuwa daga halaye da magani waɗanda aka gwada a cikin yawan mutane mai yawa. Kuma bãbu wanda yake jinkirtar da tsufa daga gare su, kuma amma suna jinkirta wa mutuwa shẽkaru, kuma mafi yawansu sunã kashe kaɗan kõ kuwa bãbu kõme.
Aiki na jiki. Kungiyar Lafiya ta Duniya tana shawartar minti 150 zuwa 300 na aiki mai tsanani, ko kuma minti 75 zuwa 150 na aiki mai karfi, a duk wata, tare da ƙarfafa ƙwayoyin jiki a cikin kwanaki biyu ko fiye da haka, kuma ga masu girman shekaru, horar da daidaito don hana faɗuwa. Aikin da ake yi a kullum yana da alaka da rage hadarin kamuwa da cututtukan zuciya, ciwon zuciya, cututtukan sukari na nau’i 2, cututtukan kansa da dama, rashin lafiyar zuciya da kuma rashin hankali (WHO, 2020). Kuma, lalle ne, haƙĩƙa, Allah Mai hikima ne, Mai jin ƙai.

Ba ta shan sigari. Mutanen da suka daina shan sigari kafin shekaru 40 suna kauce wa fiye da kashi 90 na haɗarin mutuwar da ke faruwa daga ci gaba (Jha et al., 2013). Ya hana a duk wani rãyuwar taimako.
Abubuwan da suka shafi jini da cholesterol. A cikin binciken SPRINT, kulawa mai tsanani na jini ya rage abubuwan zuciya da mutuwar, kuma ya rage rashin fahimtar sauki (SPRINT MIND, 2019). Ciwon jini mai tsanani ba ya nuna alamun cututtuka, don haka auna shi shine hanya daya tilo da za a iya sani.

Diet. A cikin binciken PREDIMED, abincin Mediterranean wanda aka cika da man zaitun ko nutsan ya rage manyan abubuwan zuciya da kashi 30 idan aka kwatanta da abinci mai ƙarancin fat (Estruch et al., 2018). WHO ta ce babu wani mataki na shan giya da yake amintacce ga lafiya; kaɗan ya fi kyau.
Sleep. Matasa ana shawartar su da su yi barci na tsawon sa’o’i bakwai a dare ta hanyar (Watson et al., 2015); barcin da ya yi tsawo ko kuma wanda aka shafa yana da alaka da ciwon zuciya da kuma cututtukan metabolism, kuma apnea na barci yana da yawa kuma ana iya magance shi.
Haɗin jama’a. A cikin wani babban meta-analysis, mutane da karfi dangantaka na zamantakewa sun kasance kusan 50 bisa dari mafi girman yiwuwar rayuwa a kan lokacin bincike (2010).
Jin, gani da allurai. Rashin jin shine mafi girman ma’aunin haɗarin canzawa na mutum don rashin hankali wanda aka sani ta Hukumar Lancet, wacce ke haɗe kashi 45 cikin dari na lokutan rashin hankali zuwa ma’aunin 14 masu canzawa (Livingston et al., 2024). A cikin binciken ACHIEVE, wani mataki na sauraro ya rage asarar fahimta da kashi 48 cikin dari a cikin shekaru uku a tsakanin masu tsufa masu haɗari (Lin et al., 2023). Wani bincike na halitta a Wales ya gano cewa rigakafin shingles an bi shi da kashi 20 cikin dari kaɗan na gwaje-gwajen rashin hankali a cikin shekaru bakwai (Eyting et al., 2025).

A lokacin da wuraren ke canjawa. Mafi girman nasarori sun zo ne a lokacin da al’umma suka canja tare. A Arewacin Kareliya, Finland, wani shirin yanki-da-yanki daga 1972 ya rage shan sigari, cholesterol da kuma zafin jini, da mutuwar cututtukan zuciya a tsakanin mutane masu shekaru 35 zuwa 64 sun fadi da kashi 82 cikin dari a cikin maza da kashi 84 cikin dari a cikin mata a shekarar 2012 (Jousilahti et al., 2016; Puska et al., 2016). Bayan da Scotland ta haramta shan sigari a wuraren jama’a masu kulle a cikin 2006, asibitocin asibitoci don harin zuciya da kuma angina mai rashin daidaito sun fadi da kashi 17 cikin dari a cikin shekara (Pell et al., 2008). A cikin binciken FINGER na Finland, wani shirin shekaru biyu na abinci, motsa jiki, horar da kwakwalwa da kuma duba jijiyoyin jini ya inganta tunani da tunawa a cikin mutane masu haɗarin kamuwa da cuta (Ngandu et al., 2015), kuma a Taketoyo, Japan, mutanen da suka fi girma waɗanda suka halarci salons na jama’a sun kasance kusan rabin yiwuwar samun rashin iya aiki a cikin shekaru biyar (Hikichi et al., 2015).
Mafi ƙarfin mafita na tsawon rai da aka yi gwaji a baya ba su da tsada: motsa jiki, barci, kada ku sha giya kuma ku kasance masu haɗin kai. Kuma ilmin zamani mai kyau yana nufin ya ƙãra musu, bã ya musanya su.
Yadda rayuwar lafiya mai tsawo za ta canza al’umma
Duniya tana fuskantar wani canji na jama’a wanda bai taba faruwa ba a baya. Bisa ga Majalisar Dinkin Duniya, adadin haihuwar duniya yanzu shine 2.25 na haihuwar mace daya, ya sauka daga 3.31 a cikin 1990; fiye da rabin dukkan kasashen da yankuna suna da yawan haihuwa a ƙasan matakin maye gurbin kusan 2.1, kuma kusan ɗaya cikin biyar yana ƙasa da 1.4. Yawan jama’ar duniya, 8.2 biliyan a cikin 2024, ana tsammanin zai kai kusan 10.3 biliyan a cikin tsakiyar 2080s kuma ya fadi kadan zuwa 10.2 biliyan ta hanyar 2100. A cikin kasashe da yankuna 63, masu rike da kashi 28 na al’ummar duniya, yawan jama’a ya kai ga mafi girma. A ƙarshen 2070s, mutane masu shekaru 65 da sama ana tsammanin za su fi yawan yara waɗanda ke ƙasa da shekara 18 (UN World Population Prospects 2024). Dalilin da ya sa yawan haihuwa ke karuwa, da kuma dalilin da yasa Local Solar System Foundation take goyon bayan ilimi da zaɓi na gaskiya ga kowace iyali, an bayyana su a shafinmu na population, consumption and resources.
A kan bayyana yawan jama’a mai shekaru da yawa a matsayin nauyi: ma’aikata kaɗan suna tallafawa masu ritaya da yawa. Ma’aunin ma’aunin, rashin dogaro da shekaru, yana lissafa mutane masu shekara 65 da sama ga kowane mutum 100 masu shekaru 20 zuwa 64. An kiyasta daga adadin Majalisar Dinkin Duniya, ya kasance 18 ga duniya a cikin 2024 kuma ana hasashen zai kai 29 a cikin 2050 da 44 a cikin 2100; a Japan yana da shekaru 55 (UN World Population Prospects 2024).
“Tsãwa bã ta zama adadi mai ƙayyadaddun lõkatai ba.”
Wannan adadi ya yi zato cewa mutum mai shekaru 65 a shekarar 2100 zai zama kamar wanda yake da shekaru 65 a shekarar 1950. Masu nazarin al’umma Warren Sanderson da Sergei Scherbov sun yi zargin cewa wannan yana haifar da kuskure. Sun yi shawara kan a auna shekarun da mutane suka bar su rãyu, ba shekarun da suka rãyu ba, kuma sun nuna cewa jama’a na iya “rayuwa mai kyau” ta wannan mataki har ma da lokacin da yawansu ya karu (Sanderson da Scherbov, 2005; Sanderson da Scherbov, 2010). Wani nau’i na ƙayyade iyakar shekarun da ake tsammani na rayuwa ya ragu zuwa kasa da shekaru 15: ga mata masu Faransanci, wannan ya kasance 58 a cikin 1900 kuma kusan 75 a cikin 2012 (Sanderson da Scherbov, 2015).
Kalmar maɓalli healthy ce. A fadin duniya, tattalin arzikin rayuwa ya karu daga shekaru 66.8 zuwa 73.1 tsakanin 2000 da 2019, yayin da bambancin tsakanin tattalin arzikin rayuwa da tattalin arzikin rayuwar lafiya ya fadada daga shekaru 8.5 zuwa 9.6 (WHO Global Health Observatory; Garmany da Terzic, 2024). Wasu shekarun da ake kashewa a cikin rashin lafiya suna kara wa iyalai da tsarin kiwon lafiya na kasar nan matsaloli. Shekaru masu yawa a cikin lafiya mai kyau suna da bambanci: mutane za su iya ci gaba da aiki idan sun so, kula da wasu, yin aikin hajji, koyon abubuwa da kuma bayar da gudummawa. Wannan shi ne dalilin da ya sa kimiyya a kan wannan shafi tana da muhimmanci ga jama’a, ba kawai ga mutane ba.
Wannan shi ne misali, ba wani hasashe ba. Ta yi amfani da adadin jama’ar da Majalisar Dinkin Duniya ta yi hasashensu kuma ta tambayi wata tambaya: idan mutane suka samu shekaru masu lafiya da kuma shekarun da suke da su na daina aiki kuma suna bukatar karin goyon baya sun tashi tare da su, yaya za a canza daidaito? Idan wannan layin ya motsa daga 65 zuwa 70, duniyar shekarar 2100 za ta sami mutane 31 masu shekaru ga kowanne mutum 100 na shekara mai aiki a matsayin 44; a shekara ta 75, kusan 21, kusa da matakin yau. An yi zaton cewa shekarun da aka kara suna da kyau, cewa aikin yi da kuma biyan albashi na iya canjawa, kuma cewa riba ta kai ga kowa, ba ma masu arziki kawai ba.
Bayan haka, lafiyar iyaye
Waɗannan uwayen suna da ‘ya’ya a wani lokaci na ƙarshe a kusa da dukansu. A cikin kasashen OECD, yawan shekarun uwaye a lokacin haihuwarsu ta farko ya karu daga 26.4 a shekarar 2000 zuwa 29.6 a shekarar 2024 (OECD Family Database). Ma’aurata suna nuna alamun tsufa a farkon lokacin da suke da yawa fiye da sauran tishu a cikin jiki (Garrison, 2026), kuma rashin haihuwa a ƙarshen shekaru goma sha uku da arba’in yana iya hana yawan yara da mutane waɗanda suka fara bayan haka za su iya samun. Binciken kan tsufa mai yawa yanzu ya zama wani bangare na geroscience: misali, binciken VIBRANT a Jami’ar Columbia ya gwada ko rage adadin rapamycin zai iya rage rasa ƙwai a cikin mata masu shekaru 35 zuwa 45 (ClinicalTrials.gov NCT05836025); sakamakonsa bai fito ba har yanzu. Idan za a iya rage tsananin tsufa na haihuwa, mutane da suke so su sami yara za su iya yin hakan nan gaba, ba tare da wani yunkuri na rufe kofar ba.
Me ya sa masu nazarin jama’a ke tsammanin karuwar za ta ci gaba
Yana da muhimmanci a kasance gaskiya game da ra’ayin maƙiyi. The Global Burden of Disease forecasters expect 155 of 204 countries and territories to have fertility below replacement by 2050 and 198 by 2100; Daga cikin 47 kasashen da yawan haihuwa ya karu, guda uku ne kawai suka dawo a sama da canjin (GBD 2021 Fertility and Forecasting Collaborators, 2024). Majalisar Dinkin Duniya ta yanke hukunci cewa kasashen da ke da yawan haihuwa mai yawa wadanda al’ummarsu ta kai ga mafi girma ba za su iya dawowa zuwa canji ba cikin shekaru 30 (UN World Population Prospects 2024). Wasu masana demography sun bayyana wani mummunan matsayin ƙarancin haihuwa, wanda a ciki ƙarni masu ƙaranci, ƙananan girman iyali da matsin tattalin arziki suna ƙarfafa juna (Lutz, Skirbekk da Testa, 2006), kuma masana kimiyya na tattalin arziki Dean Spears da Michael Geruso sun yi zargin cewa ba tare da canji ba, yawan jama’ar duniya zai iya raguwa har tsawon lokaci bayan ya kai mafi girmansa (Spears da Geruso, 2025). Rayuwa mai tsawo ba ta warware wannan ba: suna raguwa da sauri, amma a cikin lokaci mai tsawo, yawan jama’a wanda yake da yawa kaɗan yana ci gaba da ragewa.
Matsayinmu: rashin daidaituwa matsala ce ta lokaci
Dakata Local Solar System Wannan shi ne dalilin da ya sa aka yi wannan hukunci. QOCIResult, wani canji don daidaita zuwa a maimakon wani cikas na dindindin. Munã gabatar da wannan a matsayin zance, tare da dalilanmu da hujjõji waɗanda ke tabbatar da shi ko kuma ba haka ba.
A’a, sunã da wata hujja.
- Yawan rayuwa mai lafiya yana nufin akwai bukatar haihuwar yara kaɗan don samun adadin jama’a mai daidaito. A cikin jama’a da ba su girma ko kuma suka yi kasa, girmansu ya daidaita da adadin haihuwa a kowace shekara wanda aka ninka shi da tattalin arzikin rayuwa a lokacin haihuwa, wata alamar farko ta demography (Preston, Heuveline da Guillot, 2001). Idan an samu karuwar tattalin arziki daga kusan shekaru 73 zuwa 90, za a iya kiyaye yawan jama’a da kashi biyar na adadin haihuwar da ake samu a kowace shekara.
- Lafiya, ba shekarun ba, ita ce ke tantance wanda yake bukatar taimako. Idan ilimin zamantakewar mutum ya dakatar da cututtukan da suka shafi shekaru har zuwa shekaru kadan, to adadin dogaro na iya zama kusa da na yau duk da cewa jama’a suna girma, kamar yadda hoton sama ya nuna.
- A tsawo da haihuwa window za a iya barin mutane su sami yara da suke so. Idan haihuwa tsufa za a iya rage da aminci, bayan haihuwa ba zai zama nufin yara kaɗan.
- Fertility has recovered before. Among the most developed countries, some studies found that further progress in development was associated with rising fertility (Myrskylä, Kohler and Billari, 2009), especially where work and family life are easier to combine (Luci-Greulich and Thévenon, 2014), though this finding is disputed (Harttgen and Vollmer, 2014).
- A mai da hankali ga ragewa yana ba da lokaci don canjawa. Majalisar Dinkin Duniya tana hasashen karuwar sauri da kuma karuwa a wannan karni, ba tashin hankali ba, wanda ke barin shekaru da dama domin ci gaban kimiyya, aiki da kuma dokar iyali don canjawa.
Me zai yi gwajinsa? Sanarwar za ta samu goyon baya idan: tattalin rayuwar lafiya ya tashi da sauri fiye da tattalin rayuwa, yana rufe ɓangaren; wani bincike ya nuna cewa wata hanyar shiga tana jinkirta cututtukan shekaru da dama a lokaci guda, kamar yadda TAME aka tsara don yin hakan; haihuwar a cikin shekaru masu girma sun karu sosai don haka yawan iyalai ya daina faduwa; kuma hasashen dogaro ga shekarun da suka wuce wanda aka kiyasta ta hanyar lafiya, maimakon ta hanyar shekaru masu daidaituwa, suna zama masu daidaito. Za ta yi rauni idan bambancin shekaru masu lafiya ya ci gaba da fadada, idan gwaje-gwajen farko na rapamycin, senolytics da sake tsarawa sun kasa, kuma idan yawan haihuwar ya ci gaba da raguwa har ma inda iyaye ke da rayuwar lafiya mai tsawo, goyon baya mai kyau da zaɓi na gaskiya. Za mu bi da shaidar kuma mu sabunta wannan shafi kamar yadda ya zo.
Duniya mai yawan mutane kaɗan da suke rayuwa tsawon lokaci za ta iya zama wata duniyar da take da haske, wannan shi ne dalilin da ya sa wannan tambaya ke da alaƙa da aikin Local Solar System Foundation a kan hadin kai tsakanin mutane da albarkatu.
Yi hankali: kayan haɗi, asibitoci da gwajin kanka
Organizers doing this work
Waɗannan kungiyoyi masu zaman kansu suna wallafa abin da suke yi kuma suna bayar da rahoton sakamakon da za a iya auna su. Idan kana so ka tallafawa matasa masu lafiya, to ka duba aikinsu kuma ka yi tunani kan bayar da gudummawa gare su kai tsaye, ta hanyar shafukan yanar gizo na su. Dakata Local Solar System Bã ya da wata zumunta da kõwa daga gare su. Kuma bã ya karɓar kõme daga gare su. A gabãnin ka bã su, ka karanta dukkan ƙungiya’s nata rahoton shekara-shekara da kuma asusun.
- HelpAge International (United Kingdom, registered charity 288180). Yana aiki tare da kungiyoyi masu hadin gwiwa a kasashen da dama don haka mutanen da suka wuce shekarun su sami damar samun kulawar lafiya, kulawar zamantakewa da tsaron kudin shiga, kuma yana magana game da hakkinsu.
- Age UK (United Kingdom, registered charity 1128267). Yana bayar da goyon baya ga masu shekaru masu fama da talauci, tsare-tsaren da kuma rashin kulawa, da bincike da kamfen don inganta tsarin.
- British Heart Foundation (United Kingdom, registered charity 225971). The largest independent funder of research into heart and circulatory disease in the United Kingdom. (a cikin Ingilishi)
- American Heart Association (United States, tax-exempt non-profit). Ya na bada tallafi ga bincike a kan cututtukan zuciya da ciwon zuciya, kuma yana gudanar da shirye-shiryen jama’a kan hana kamuwa da su.
- Alzheimer’s Society (United Kingdom, registered charity 296645) da kuma Alzheimer’s Association (United States, tax-exempt non-profit). Dukkansu suna goyon bayan mutane da ke rayuwa da cututtukan zuciya da masu kula da su, kuma suna tallafawa bincike a kan hanawa, magani da kulawa.
Yadda zaka iya taimaka
- Ku yi farawa da abin da aka tabbatar. Ka yi tafiya kaɗan a yau, ka ƙara ƙarfi da daidaitattun motsa jiki, kuma ka tambayi wani masanin lafiya ya duba zafin jininka.
- Ya yi gwajin jinka da ganinka, kuma ya yi wa mahaifiyarka da ubanninka gargadi su yi kama da haka.
- Ka ci gaba da kasancewa cikin haɗin kai. Ka kira wani wanda ba ka yi magana da shi ba na ɗan lokaci; Ka kira wani maƙwabci mai nisa zuwa wani abu.
- Ka bi gwaje-gwajen, ba tallace-tallace. Amsoshin daga gwaje-gwajen da aka yi rajista, an wallafa su a cikin littattafai masu nazari, sune abin da ke da muhimmanci.
- Ka yi shakka game da zargin mu’ujiza, kuma ka raba wannan shafi idan ka ga daya.
- Ku taimake mu mu kiyaye wannan shafi daidai. Masu bincike, likitoci da mafatanci za su iya yin aiki na kyauta a kan tashar tallafi.
Sources and further reading
- Kennedy da sauran (2014), Geroscience: linking aging to chronic disease, Cell 159
- da sauransu (2013), Hanyoyin da ake samun tsufa, Cell 153
- da sauransu (2023), Hallmarks of aging: an expanding universe, Cell 186
- Dakata (2013), Sani da kuma dawowar tattalin arziki daga tsufa mai tsawo na iya tabbatar da sabon la’akari ga bincike na likita, Labaran Lafiya 32
- Scott, Ellison da Sinclair (2021), Ma’anar tattalin arzikin yin niyya ga tsufa, Nature Aging 1
- Ma’aikatar lafiya ta kasar Amurka (2026), NHIS Adult Summary Health Statistics, 2025, da kuma NHIS 2025 sample adult file
- Jami’ar Kanjamau ta Kasashen Amurka, SEER*Explorer, yawan kamuwa da kanjamau bisa shekaru, 2019 zuwa 2023
- Manly et al. (2022), Tattauna yawan kamuwa da ciwon zuciya da kuma rashin fahimtar sauki a Amurka, JAMA Neurology 79
- Garmany da Terzic (2024), Gabancin lafiyar duniya-gabancin rayuwa a tsakanin kasashe 183 na kungiyar kiwon lafiya ta duniya, JAMA Network Open 7
- Jami’ar Tarayyar Amurka ta National Institute on Aging, Interventions Testing Program
- Vézina, Kudelski da Sehgal (1975), Rapamycin (AY-22,989), wani sabon maganin rigakafin kwari, Journal of Antibiotics 28
- Harrison da sauran (2009), Rapamycin da aka ci a ƙarshe a rayuwar ya faɗaɗa tsawon rayuwa a cikin ƙwayoyin cuta masu haɗari, Nature 460
- da (2011), Rapamycin, amma ba resveratrol ko simvastatin, ya fadada rayuwar kifi na halitta da yawa, Journals of Gerontology A 66
- da (2014), Rapamycin-mediated lifespan increase in mice is dose and sex dependent, Aging Cell 13
- Dakata (2014), mTOR inhibition improves immune function in the elderly, Science Translational Medicine 6
- Dakata (2018), TORC1 hana inganta aikin rigakafi da rage cututtuka a cikin matasa, *Science Translational Medicine * 10
- Dakata (2021), Targeting the biology of ageing with mTOR inhibitors to improve immune function in elderly adults: phase 2b and phase 3 randomised trials, Lancet Healthy Longevity 2
- Dakata (2025), Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results, Aging 17
- Lee, Kuerec da Maier (2024), [Targeting tsufa tare da rapamycin da kuma derivatives a cikin mutane: wani nazari na tsarin](https://doi.org/10.1016/S2666-7568(23) 00258-1), *Lancet lafiya Longevity * 5
- Dakata (2012), Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity, Science 335
- National Library of Medicine, DailyMed: sirolimus prescribing information
- da sauransu (2008), Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor, PLOS Biology 6
- Dakata (2011), Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders, Nature 479
- Dakata (2016), Naturally occurring p16Ink4a-positive cells shorten healthy lifespan, Nature 530
- Dakata (2015), The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs, Aging Cell 14
- Dakata (2018), Senolytics inganta jiki aiki da kuma kara rayuwar a cikin tsufa, Nature Medicine 24
- Dakata (2018), Fisetin shi ne senotherapeutic wanda ya fadada lafiya da tsawon rai, EBioMedicine 36
- Justice et al. (2019), Senolytics a cikin fibrosis na huhun idiopathic: sakamakon daga farko-in-human, bude-label, pilot bincike, EBioMedicine 40
- Dakata (2019), Senolytics decrease senescent cells in humans, EBioMedicine 47
- Dakata (2024), Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial, Nature Medicine 30
- Dakata (2023), Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial, Nature Medicine 29
- Unity Biotechnology (2025), ASPIRE mataki 2b topline sakamakon da certificate na warwarewa, Amurka Securities da Exchange Commission shigarwa
- Dakata (2016), Aikin gudanarwa na dogon lokaci na nicotinamide mononucleotide yana rage raguwa ta physiological a cikin ƙwayoyin cuta, Cell Metabolism 24
- Zhang et al. (2016), NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice, Science 352
- Harrison da sauran (2021), 17-a-estradiol da ya wuce a rayuwa ya fadada rayuwarsa a cikin matasan UM-HET3 maza kifi; nicotinamide riboside da sauran magunguna uku ba su shafar rayuwarsu a kowane jinsi, Aging Cell 20
- Dakata (2018), Cronical nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults, Nature Communications 9
- da sauransu (2021), Nicotinamide mononucleotide yana ƙara ƙwaƙwalwar ƙwaƙwalwar ƙwaƙwalwa a cikin mata masu ciwon sukari, Science 372
- Dakata (2022), An yi amfani da wannan tsari ne wajen gano cututtukan Parkinson da kuma cutar Alzheimer., * Cell Metabolism * 34
- Zhang et al. (2025), Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review, Critical Reviews in Food Science and Nutrition 65
- Dakata (2025), The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function, Journal of Cachexia, Sarcopenia and Muscle 16
- Ƙungiyar Abinci da Magunguna ta Amurka (2025), amsa ga bukatar jama’a kan NMN, doket FDA-2023-P-0872
- Dakata (2003), Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan, Nature 425
- Dakata (2006), Resveratrol na inganta lafiya da rãyuwa ta kifi a kan abinci mai yawan kcal, Nature 444
- Dakata (2008), Resveratrol dakatar da shekaru-dauke da lalacewa da kuma mimic transcriptional fannoni na abincin hana ba tare da yalwatar rayuwa, Cell Metabolism 8
- Dakata (2005), Substrate-specific activation of sirtuins by resveratrol, Journal of Biological Chemistry 280
- Dakata (2010), SRT1720, SRT2183, SRT1460, da resveratrol ba su ne masu canzawa na SIRT1, Journal of Biological Chemistry 285
- Dakata (2011), Abubuwan da Sir2 ke haifarwa a kan tsawon rai a cikin C. elegans da Drosophila, Nature 477
- GlaxoSmithKline da Sirtris Pharmaceuticals (2008), warwarewa, Amurka Securities da Exchange Commission
- da (2012), The sirtuin SIRT6 regulates lifespan in male mice, Nature 483
- Dakata (2021), Restoration na makamashi homeostasis ta SIRT6 ya fadada lafiya rayuwa, Nature Communications 12
- The Nobel Prize in Physiology or Medicine 2009 and 2012
- da (2012), Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer, EMBO Molecular Medicine 4
- Kim et al. (1994), Tattaunawa ta musamman kan aikin telomerase na mutum da kwayoyin halittar da ba su mutu ba da kuma ciwon daji, Science 266
- Telomeres Mendelian Randomization Collaboration, Haycock et al. (2017), Assashen da ke tsakanin tsayin telomere da haɗarin kamuwa da ciwon daji da cututtukan ba-neoplastic, JAMA Oncology 3
- Armanios da Blackburn (2012), The telomere syndromes, Nature Reviews Genetics 13
- da kuma (2016), Danazol treatment for telomere diseases, NEJM 374
- Takahashi da Yamanaka (2006), Inducing na pluripotent ƙwayoyin halitta daga kifi embryonic da matasa fibroblast al’adu ta hanyar defined dalilai, Cell 126
- Dakata (2016), In vivo amelioration of age-associated hallmarks by partial reprogramming, Cell 167
- Dakata (2020), Reprogramming to recover youthful epigenetic information and restore vision, Nature 588
- Dakata (2022), In vivo reprogramming na ɓangare yana canzawa da shekaru masu alaƙa da canjin molecular yayin tsufa a cikin ƙwayoyin cuta, Nature Aging 2
- da kuma (2024), Gene therapy-mediated partial reprogramming extends lifespan and reverses age-related changes in aged mice, Cellular Reprogramming 26
- Dakata (2013), Reprogramming in vivo produces teratomas and iPS cells with totipotency features, Nature 502
- Dakata (2023), In vivo reprogramming leads to premature death linked to liver and intestine failure, Nature Aging 3
- Life Biosciences (2026), FDA clearance of IND for ER-100 da first patient dosed; trial record NCT07290244
- Sanarwar Kamfani: Altos Labs (2022), Retro Biosciences (2026), NewLimit (2026); da MIT Technology Review (2023) a kan Retro Biosciences
- Dakata (2025), review of the Interventions Testing Program, Journals of Gerontology A 80
- Harrison da sauran (2014), Acarbose, 17-α-estradiol, da nordihydroguaiaretic acid sukan kara tsawon rayuwar kifi a maza, Aging Cell 13
- da kuma (2016), Longer rayuwa a cikin maza kifi da aka yi wa magani da wani estrogenic agonist mara karfi, anti-oxidant, α-glucosidase inhibitor ko Nrf2-inducer, Aging Cell 15
- da kuma (2008), Nordihydroguaiaretic acid da aspirin suna kara tsawon rayuwar kwayoyin halittar maza masu bambancin jinsi, Aging Cell 7
- da (2019), Glycine supplementation extends lifespan of male and female mice, Aging Cell 18
- da (2020), Canagliflozin ya fadada tsawon rayuwarsa a cikin ƙwayoyin cuta masu haɗari amma ba mata ba, JCI Insight 5
- da kuma (2022), Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice, Aging Cell 21
- Dakata (2014), Za a iya samun mutane da suka kamu da ciwon sukari na nau’i 2 su rayu tsawon lokaci fiye da waɗanda ba su yi ba?, Ciwon sukari, Ciwon ciki da Metabolism 16
- Dakata (2016), Metformin a matsayin kayan aiki don yin amfani da tsufa, Cell Metabolism 23
- Dakata (2022), Reassessing the evidence of a survival advantage in type 2 diabetes treated with metformin compared with controls without diabetes, International Journal of Epidemiology 51
- Dakata (2019), Metformin ya hana canje-canjen mitochondrial zuwa horon motsa jiki na aerobic a cikin manya, Aging Cell 18
- Dakata (2019), Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults (MASTERS), Aging Cell 18
- Lincoff et al. (2023), Semaglutide da sakamakon jijiyoyin zuciya a cikin ciwon sukari ba tare da ciwon sukari ba (SELECT), NEJM 389
- Xie, Choi da Al-Aly (2025), Mapping da inganci da haɗarin GLP-1 mai karɓar agonists, Nature Medicine 31
- Dakata (2026), Oral semaglutide in early Alzheimer’s disease (evoke and evoke+), The Lancet 407
- Dakata (2017), Karin Caloric yana inganta lafiya da rãyuwa na rhesus monkeys, Nature Communications 8
- Dakata (2019), 2 shekarun hana calorie da haɗarin cardiometabolic (CALERIE), Lancet Diabetes & Endocrinology 7
- Dakata (2023), Effect of long-term caloric restriction on DNA methylation measures of biological ageing, Nature Aging 3
- Dakata (2005), Rejuvenation na aged progenitor cells ta hanyar damuwa ga wani dan lokaci systemic yanayi, Nature 433
- Dakata (2020), Rejuvenation na uku germs layuka tishu ta hanyar musanya da jinin zamani plasma tare da saline-albumin, Aging 12
- Dakata (2015), GDF11 yana karuwa da shekaru kuma yana hana sake dawo da ƙwayoyin ƙwaƙwalwa, Cell Metabolism 22
- Dakata (2025), Analysis na Multi-omics ya bayyana biomarkers da ke taimakawa ga haihuwar haihuwar halitta a matsayin amsa ga musayar plasma mai magani, Aging Cell 24
- Dakata (2020), A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease (AMBAR), Alzheimer’s & Dementia 16
- US Food and Drug Administration (2019), An yi gargadin masu amfani da plasma kada su rika karbar plasma daga masu bada plasma
- Horvath (2013), DNA methylation age of human tissues and cell types, Genome Biology 14
- Dakata (2013), Genome-wide methylation profiles reveal quantitative views of human ageing rates, Molecular Cell 49
- Dakata (2018), An epigenetic biomarker of aging for lifespan and healthspan (PhenoAge), Aging 10
- Dakata (2019), DNA methylation GrimAge strongly predicts lifespan and healthspan, Aging 11
- Dakata (2022), DunedinPACE, wani mai nuna methylation na DNA na sauri na tsufa, eLife 11
- Dakata (2016), DNA methylation-based measures of biological age: meta-analysis predicting time to death, Aging 8
- Dakata (2022), A computational solution for bolstering reliability of epigenetic clocks, Nature Aging 2
- Hukumar Lafiya ta Duniya (2020), Tallafin ayyukan jiki da kuma halayen zama
- da (2013), Hadarin shan sigari a karni na 21 da amfanin da ya samo daga dakatar da shi a Amurka, NEJM 368
- SPRINT MIND Investigators (2019), Tasirin kula da zafin jini mai yawa akan rashin hankali, JAMA 321
- Dakata (2018), Yaki da cututtukan zuciya da abincin Mediterranean, NEJM 378
- Watson et al. (2015), Idan ka yi barci da kyau, za ka samu lafiya, Barci 38
- Dakata (2010), Haɗin kai na zamantakewa da haɗarin mutuwar, PLOS Medicine 7
- da kuma (2024), Kashewa, dakatar da cutar, da kulawa: rahoton 2024 na kwamitin Lancet, The Lancet 404
- Dakata (2023), Tattaunawa game da kulawa da ilimi na lafiya don rage raguwa ta fahimta (ACHIEVE), The Lancet 402
- Eyting et al. (2025), A natural experiment on the effect of herpes zoster vaccination on dementia, Nature
- Dakata (2022), Takaddun matakai na yau da kullum da mutuwar duk-mutuwar: meta-analysis na 15 cohorts na duniya, The Lancet Public Health 7
- Da sauransu (2016), 40-year CHD mortality trends and the role of risk factors in mortality decline: the North Karelia Project experience, Global Heart 11
- Dakata (2016), Labaran baya, dokoki, aiwatarwa da kuma kwarewar gabaɗaya na shirin North Karelia, Global Heart 11
- Dakata (2010), Tasirin shekaru goma sha biyar a cikin abubuwan haɗarin zuciya da jijiyoyi a Finland, International Journal of Epidemiology 39
- Dakata (2008), Dokar hana shan sigari da kulawa a asibitoci ga cututtukan zuciya masu tsanani, NEJM 359
- Dakata (2015), A 2 shekara multidomain dakatar da lalacewa na fahimta a cikin hadarin matasa masu shekaru (FINGER), The Lancet 385
- Dakata (2015), Tasirin shirin hadin gwiwar al’umma na kyautata hulɗar jama’a kan hana rashin aikin yi ga masu shekaru: binciken JAGES Taketoyo, Journal of Epidemiology and Community Health 69
- United Nations, Department of Economic and Social Affairs, Population Division (2024), World Population Prospects 2024: Summary of Results and data files
- Sanderson da Scherbov (2005), Average remaining lifetimes can increase as human populations age, Nature 435
- Sanderson da Scherbov (2010), Remeasuring aging, Science 329
- Sanderson da Scherbov (2015), Faster ƙari a cikin mutum rayuwa tsammani zai iya haifar da sauri jama’a tsufa, PLOS daya 10
- World Health Organization, Global Health Observatory: life expectancy and healthy life expectancy
- Sashen Hausa na BBC, Sabon littafin Malam Aminu Kano
- Garrison (2026), Beyond reproduction: the ovary as a systemic regulator of female health and aging, PLOS Biology 24
- Ƙara NCT05836025
- GBD 2021 Fertility and Forecasting Collaborators (2024), Global fertility in 204 countries and territories, 1950 to 2021, with forecasts to 2100, The Lancet 403
- Lutz, Skirbekk da Testa (2006), The low-fertility trap hypothesis, Vienna Yearbook of Population Research
- Spears da Geruso (2025), After the Spike: Population, Progress, and the Case for People, Simon & Schuster
- Preston, Heuveline da Guillot (2001), Demography: Measuring and Modeling Population Processes, Blackwell
- Myrskylä, Kohler da Billari (2009), Advances in development reverse fertility declines, Nature 460
- Luci-Greulich da Thévenon (2014), Shin ci gaban tattalin arziki ‘ya haifar’ da sake karuwar yawan haihuwa?, Janarun Afirka na Mutanen Duniya 30
- Harttgen da Vollmer (2014), A reversal in the relationship of human development with fertility?, Demography 51
- MIT Technology Review (2015), 2015 a cikin biomedicine
- Bayanan tallafi daga Kwamitin tallafi na lissafin Ingilishi da Wales da kuma halin Amurka na ba da gudummawa daga ProPublica Nonprofit Explorer